1-13 of 13
Marco Colleoni
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

The Immune-Related 27-Gene Signature DetermaIO Predicts Response to Neoadjuvant Atezolizumab plus Chemotherapy in Triple-Negative Breast Cancer

Matteo Dugo, Chiun-Sheng Huang, Daniel Egle, Begoña Bermejo, Claudio Zamagni, Robert S. Seitz, Tyler J. Nielsen, Marc Thill, Antonio Antón-Torres, Stefania Russo, Eva Maria Ciruelos, Brock L. Schweitzer, Douglas T. Ross, Barbara Galbardi, Richard Greil, Vladimir Semiglazov, Balázs Gyorffy, Marco Colleoni, Catherine M. Kelly, Gabriella Mariani, Lucia Del Mastro, Olivia Blasi, Maurizio Callari, Lajos Pusztai, Pinuccia Valagussa, Giuseppe Viale, Luca Gianni, Giampaolo Bianchini
Journal: Clinical Cancer Research
Clin Cancer Res (2024) 30 (21): 4900–4909.
https://doi.org/10.1158/1078-0432.CCR-24-0149
Published: 01 November 2024
View article titled, The Immune-Related 27-Gene Signature DetermaIO Predicts Response to Neoadjuvant Atezolizumab plus Chemotherapy in Triple-Negative Breast Cancer
Open the PDF for The Immune-Related 27-Gene Signature DetermaIO Predicts Response to Neoadjuvant Atezolizumab plus Chemotherapy in Triple-Negative Breast Cancer in another window
Includes: Supplementary data
Journal Articles

HER2DX Genomic Assay in HER2-Positive Early Breast Cancer Treated with Trastuzumab and Pertuzumab: A Correlative Analysis from the PHERGain Phase II Trial

Antonio Llombart-Cussac, Jose Pérez-García, Fara Brasó-Maristany, Laia Paré, Guillermo Villacampa, Maria Gion, Peter Schmid, Marco Colleoni, Manuel R. Borrego, Patricia Galván, Joel S. Parker, Wesley Buckingham, Charles M. Perou, Patricia Villagrasa, Jose A. Guerrero, Miguel Sampayo-Cordero, Mario Mancino, Aleix Prat, Javier Cortés
Journal: Clinical Cancer Research
Clin Cancer Res (2024) 30 (18): 4123–4130.
https://doi.org/10.1158/1078-0432.CCR-24-0464
Published: 13 September 2024
View article titled, HER2DX Genomic Assay in HER2-Positive Early Breast Cancer Treated with Trastuzumab and Pertuzumab: A Correlative Analysis from the PHERGain Phase II Trial
Open the PDF for HER2DX Genomic Assay in HER2-Positive Early Breast Cancer Treated with Trastuzumab and Pertuzumab: A Correlative Analysis from the PHERGain Phase II Trial in another window
Includes: Supplementary data
Journal Articles

Fine-Tuning Adjuvant Endocrine Therapy for Early-Stage Breast Cancer: An Expert Consensus on Open Issues for Future Research

Fabio Conforti, Laura Pala, Tommaso De Pas, Emma Zattarin, Chiara Catania, Emilia Cocorocchio, Giovanna Rossi, Daniele Laszlo, Marco Colleoni, Alberto Zambelli, Gabriel N. Hortobagyi, Javier Cortes, Martine J. Piccart, Mitch Dowsett, Richard D. Gelber, Giuseppe Viale
Journal: Clinical Cancer Research
Clin Cancer Res (2024) 30 (6): 1093–1103.
https://doi.org/10.1158/1078-0432.CCR-23-1836
Published: 15 March 2024
View article titled, Fine-Tuning Adjuvant Endocrine Therapy for Early-Stage Breast Cancer: An Expert Consensus on Open Issues for Future Research
Open the PDF for Fine-Tuning Adjuvant Endocrine Therapy for Early-Stage Breast Cancer: An Expert Consensus on Open Issues for Future Research in another window
Journal Articles

Differential Benefit of Metronomic Chemotherapy Among Triple-Negative Breast Cancer Subtypes Treated in the IBCSG Trial 22–00

Andrea Joaquin Garcia, Mattia Rediti, David Venet, Samira Majjaj, Roswitha Kammler, Elisabetta Munzone, Lorenzo Gianni, Beat Thürlimann, István Laáng, Marco Colleoni, Sherene Loi, Giuseppe Viale, Meredith M. Regan, Laurence Buisseret, Françoise Rothé, Christos Sotiriou
Journal: Clinical Cancer Research
Clin Cancer Res (2023) 29 (23): 4908–4919.
https://doi.org/10.1158/1078-0432.CCR-23-1267
Published: 01 December 2023
View article titled, Differential Benefit of Metronomic Chemotherapy Among Triple-Negative Breast Cancer Subtypes Treated in the IBCSG Trial 22–00
Open the PDF for Differential Benefit of Metronomic Chemotherapy Among Triple-Negative Breast Cancer Subtypes Treated in the IBCSG Trial 22–00 in another window
Includes: Supplementary data
Journal Articles

Overall Survival with Palbociclib and Fulvestrant in Women with HR+/HER2− ABC: Updated Exploratory Analyses of PALOMA-3, a Double-blind, Phase III Randomized Study

Massimo Cristofanilli, Hope S. Rugo, Seock-Ah Im, Dennis J. Slamon, Nadia Harbeck, Igor Bondarenko, Norikazu Masuda, Marco Colleoni, Angela DeMichele, Sherene Loi, Hiroji Iwata, Ben O'Leary, Fabrice André, Sibylle Loibl, Eustratios Bananis, Yuan Liu, Xin Huang, Sindy Kim, Maria Jose Lechuga Frean, Nicholas C. Turner
Journal: Clinical Cancer Research
Clin Cancer Res (2022) 28 (16): 3433–3442.
https://doi.org/10.1158/1078-0432.CCR-22-0305
Published: 15 August 2022
View article titled, Overall Survival with Palbociclib and Fulvestrant in Women with HR<sup>+</sup>/HER2<sup>−</sup> ABC: Updated Exploratory Analyses of PALOMA-3, a Double-blind, Phase III Randomized Study
Open the PDF for Overall Survival with Palbociclib and Fulvestrant in Women with HR<sup>+</sup>/HER2<sup>−</sup> ABC: Updated Exploratory Analyses of PALOMA-3, a Double-blind, Phase III Randomized Study in another window
Includes: Supplementary data
Journal Articles

Updated Overall Survival of Ribociclib plus Endocrine Therapy versus Endocrine Therapy Alone in Pre- and Perimenopausal Patients with HR+/HER2− Advanced Breast Cancer in MONALEESA-7: A Phase III Randomized Clinical Trial

Yen-Shen Lu, Seock-Ah Im, Marco Colleoni, Fabio Franke, Aditya Bardia, Fatima Cardoso, Nadia Harbeck, Sara Hurvitz, Louis Chow, Joohyuk Sohn, Keun Seok Lee, Saul Campos-Gomez, Rafael Villanueva Vazquez, Kyung Hae Jung, K. Govind Babu, Paul Wheatley-Price, Michelino De Laurentiis, Young-Hyuck Im, Sherko Kuemmel, Nagi El-Saghir, Ruth O'Regan, Claudia Gasch, Nadia Solovieff, Craig Wang, Yongyu Wang, Arunava Chakravartty, Yan Ji, Debu Tripathy
Journal: Clinical Cancer Research
Clin Cancer Res (2022) 28 (5): 851–859.
https://doi.org/10.1158/1078-0432.CCR-21-3032
Published: 01 March 2022
View article titled, Updated Overall Survival of Ribociclib plus Endocrine Therapy versus Endocrine Therapy Alone in Pre- and Perimenopausal Patients with HR<sup>+</sup>/HER2<sup>−</sup> Advanced Breast Cancer in MONALEESA-7: A Phase III Randomized Clinical Trial
Open the PDF for Updated Overall Survival of Ribociclib plus Endocrine Therapy versus Endocrine Therapy Alone in Pre- and Perimenopausal Patients with HR<sup>+</sup>/HER2<sup>−</sup> Advanced Breast Cancer in MONALEESA-7: A Phase III Randomized Clinical Trial in another window
Includes: Supplementary data
Journal Articles

Niraparib for Advanced Breast Cancer with Germline BRCA1 and BRCA2 Mutations: the EORTC 1307-BCG/BIG5–13/TESARO PR-30–50–10-C BRAVO Study

Nicholas C. Turner, Judith Balmaña, Coralie Poncet, Theodora Goulioti, Konstantinos Tryfonidis, Aafke H. Honkoop, Gabriele Zoppoli, Evangelia Razis, Oskar T. Johannsson, Marco Colleoni, Andrew N. Tutt, William Audeh, Michail Ignatiadis, Audrey Mailliez, Olivier Trédan, Antonino Musolino, Peter Vuylsteke, Maria Jose Juan-Fita, Iain R.J. Macpherson, Bella Kaufman, Luis Manso, Lori J. Goldstein, Susan L. Ellard, István Láng, Kai Yu Jen, Virginie Adam, Saskia Litière, John Erban, David A. Cameron
Journal: Clinical Cancer Research
Clin Cancer Res (2021) 27 (20): 5482–5491.
https://doi.org/10.1158/1078-0432.CCR-21-0310
Published: 15 October 2021
View article titled, Niraparib for Advanced Breast Cancer with Germline <em>BRCA1</em> and <em>BRCA2</em> Mutations: the EORTC 1307-BCG/BIG5–13/TESARO PR-30–50–10-C BRAVO Study
Open the PDF for Niraparib for Advanced Breast Cancer with Germline <em>BRCA1</em> and <em>BRCA2</em> Mutations: the EORTC 1307-BCG/BIG5–13/TESARO PR-30–50–10-C BRAVO Study in another window
Includes: Supplementary data
Journal Articles

Genomic Aberrations and Late Recurrence in Postmenopausal Women with Hormone Receptor–positive Early Breast Cancer: Results from the SOLE Trial

Elena Guerini-Rocco, Kathryn P. Gray, Caterina Fumagalli, Marta Rita Reforgiato, Isabella Leone, Paola Rafaniello Raviele, Elisabetta Munzone, Roswitha Kammler, Patrick Neven, Erika Hitre, Guy Jerusalem, Edda Simoncini, Andrea Gombos, Ines Deleu, Per Karlsson, Stefan Aebi, Jacquie Chirgwin, Vincenzo Di Lauro, Alastair Thompson, Marie-Pascale Graas, Matthew Barber, Christel Fontaine, Sibylle Loibl, Joaquín Gavilá, Katsumasa Kuroi, Bettina Müller, Seamus O’Reilly, Angelo Di Leo, Aron Goldhirsch, Giuseppe Viale, Massimo Barberis, Meredith M. Regan, Marco Colleoni
Journal: Clinical Cancer Research
Clin Cancer Res (2021) 27 (2): 504–512.
https://doi.org/10.1158/1078-0432.CCR-20-0126
Published: 19 January 2021
View article titled, Genomic Aberrations and Late Recurrence in Postmenopausal Women with Hormone Receptor–positive Early Breast Cancer: Results from the SOLE Trial
Open the PDF for Genomic Aberrations and Late Recurrence in Postmenopausal Women with Hormone Receptor–positive Early Breast Cancer: Results from the SOLE Trial in another window
Includes: Supplementary data
Journal Articles

A Randomized Placebo Controlled Phase II Trial Evaluating Exemestane with or without Enzalutamide in Patients with Hormone Receptor–Positive Breast Cancer

Ian Krop, Vandana Abramson, Marco Colleoni, Tiffany Traina, Frankie Holmes, Laura Garcia-Estevez, Lowell Hart, Ahmad Awada, Claudio Zamagni, Patrick G. Morris, Lee Schwartzberg, Stephen Chan, Ayca Gucalp, Laura Biganzoli, Joyce Steinberg, Lorenzo Sica, Maureen Trudeau, Denka Markova, Jamal Tarazi, Zhou Zhu, Thomas O'Brien, Catherine M. Kelly, Eric Winer, Denise A. Yardley
Journal: Clinical Cancer Research
Series: Author Choice
Clin Cancer Res (2020) 26 (23): 6149–6157.
https://doi.org/10.1158/1078-0432.CCR-20-1693
Published: 01 December 2020
View article titled, A Randomized Placebo Controlled Phase II Trial Evaluating Exemestane with or without Enzalutamide in Patients with Hormone Receptor–Positive Breast Cancer
Open the PDF for A Randomized Placebo Controlled Phase II Trial Evaluating Exemestane with or without Enzalutamide in Patients with Hormone Receptor–Positive Breast Cancer in another window
Includes: Supplementary data
Journal Articles

A Phase II Randomized Study of Neoadjuvant Letrozole Plus Alpelisib for Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Breast Cancer (NEO-ORB)

Ingrid A. Mayer, Aleix Prat, Daniel Egle, Sibel Blau, J. Alejandro Pérez Fidalgo, Michael Gnant, Peter A. Fasching, Marco Colleoni, Antonio C. Wolff, Eric P. Winer, Christian F. Singer, Sara Hurvitz, Laura García Estévez, Peter A. van Dam, Sherko Kümmel, Christoph Mundhenke, Frankie Holmes, Naveen Babbar, Laure Charbonnier, Ivan Diaz-Padilla, Florian D. Vogl, Dalila Sellami, Carlos L. Arteaga
Journal: Clinical Cancer Research
Series: Author Choice
Clin Cancer Res (2019) 25 (10): 2975–2987.
https://doi.org/10.1158/1078-0432.CCR-18-3160
Published: 15 May 2019
View article titled, A Phase II Randomized Study of Neoadjuvant Letrozole Plus Alpelisib for Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Breast Cancer (NEO-ORB)
Open the PDF for A Phase II Randomized Study of Neoadjuvant Letrozole Plus Alpelisib for Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Breast Cancer (NEO-ORB) in another window
Includes: Supplementary data
Journal Articles

Predictive Potential of Angiogenic Growth Factors and Circulating Endothelial Cells in Breast Cancer Patients Receiving Metronomic Chemotherapy Plus Bevacizumab

Angelica Calleri, Anna Bono, Vincenzo Bagnardi, Jessica Quarna, Patrizia Mancuso, Cristina Rabascio, Silvia Dellapasqua, Elisabetta Campagnoli, Yuval Shaked, Aron Goldhirsch, Marco Colleoni, Francesco Bertolini
Journal: Clinical Cancer Research
Clin Cancer Res (2009) 15 (24): 7652–7657.
https://doi.org/10.1158/1078-0432.CCR-09-1493
Published: 14 December 2009
View article titled, Predictive Potential of Angiogenic Growth Factors and Circulating Endothelial Cells in Breast Cancer Patients Receiving Metronomic Chemotherapy Plus Bevacizumab
Open the PDF for Predictive Potential of Angiogenic Growth Factors and Circulating Endothelial Cells in Breast Cancer Patients Receiving Metronomic Chemotherapy Plus Bevacizumab in another window
Journal Articles

Chemotherapy Is More Effective in Patients with Breast Cancer Not Expressing Steroid Hormone Receptors: A Study of Preoperative Treatment

Marco Colleoni, Giuseppe Viale, David Zahrieh, Giancarlo Pruneri, Oreste Gentilini, Paolo Veronesi, Richard D. Gelber, Giuseppe Curigliano, Rosalba Torrisi, Alberto Luini, Mattia Intra, Viviana Galimberti, Giuseppe Renne, Franco Nolè, Giulia Peruzzotti, Aron Goldhirsch
Journal: Clinical Cancer Research
Clin Cancer Res (2004) 10 (19): 6622–6628.
https://doi.org/10.1158/1078-0432.CCR-04-0380
Published: 08 October 2004
View article titled, Chemotherapy Is More Effective in Patients with Breast Cancer Not Expressing Steroid Hormone Receptors: <subtitle>A Study of Preoperative Treatment</subtitle>
Open the PDF for Chemotherapy Is More Effective in Patients with Breast Cancer Not Expressing Steroid Hormone Receptors: <subtitle>A Study of Preoperative Treatment</subtitle> in another window
Journal Articles

Detection by Denaturant Gradient Gel Electrophoresis of Tumor-specific Mutations in Biopsies and Relative Bronchoalveolar Lavage Fluid from Resectable Non-Small Cell Lung Cancer

Gianluigi Ferretti, Giuseppe Curigliano, Ugo Pastorino, Achille Cittadini, Giovanna Flamini, Maria Grazia Calabrò, Tommaso De Pas, Laura Orlando, Mario Mandalà, Marco Colleoni, Lorenzo Spaggiari, Pier Luigi Granone, Gabriella Pagliari, Filippo de Braud, Nicola Fazio, Aron Goldhirsch
Journal: Clinical Cancer Research
Clin Cancer Res (2000) 6 (6): 2393–2400.
Published: 01 June 2000
View article titled, Detection by Denaturant Gradient Gel Electrophoresis of Tumor-specific Mutations in Biopsies and Relative Bronchoalveolar Lavage Fluid from Resectable Non-Small Cell Lung Cancer
Open the PDF for Detection by Denaturant Gradient Gel Electrophoresis of Tumor-specific Mutations in Biopsies and Relative Bronchoalveolar Lavage Fluid from Resectable Non-Small Cell Lung Cancer in another window